Particle.news
Download on the App Store
4 ARTICLES
·
5h ago

Isomorphic Labs to Begin First Human Trials of AI-Designed Medicines

The DeepMind spin-off’s venture into clinical testing signals a pivotal transition from computational design to human validation.

In April 2025, Isomorphic Labs raised a $600 million in its first-ever external funding round, led by Thrive Capital.
Image
Image
Isomorphic Labs prepares to revolutionize medicine with AI-designed drugs entering human trials.

Overview

  • Isomorphic Labs plans to start human trials for its internally designed oncology and immunology candidates in July 2025, marking its first clinical tests of AI-designed therapies.
  • The company leverages DeepMind’s AlphaFold 3 system to predict protein structures and model molecular interactions that streamline drug design.
  • In 2024, Isomorphic signed major research collaborations with Novartis and Eli Lilly to co-develop AI-assisted drug discovery programs.
  • A $600 million funding round led by Thrive Capital in April 2025 strengthened its drug design engine and supported staff expansion ahead of clinical testing.
  • Isomorphic envisions enabling one-click generation of drug candidates and aims to license its AI-designed treatments after early-phase human trials.